Integra LifeSciences Holdings Corporation (NASDAQ:IART) Receives Consensus Recommendation of "Reduce" from Analysts

Integra LifeSciences Holdings Corporation (NASDAQ:IART - Get Free Report) has earned an average recommendation of "Reduce" from the nine ratings firms that are presently covering the stock, Marketbeat reports. Four analysts have rated the stock with a sell recommendation, three have given a hold recommendation and two have assigned a buy recommendation to the company. The average 1 year price objective among brokers that have issued a report on the stock in the last year is $18.63.

Several equities analysts have weighed in on IART shares. Argus raised Integra LifeSciences from a "hold" rating to a "buy" rating in a research note on Monday, March 31st. Truist Financial lowered their price objective on shares of Integra LifeSciences from $26.00 to $19.00 and set a "hold" rating on the stock in a research report on Friday, April 11th. JPMorgan Chase & Co. decreased their target price on shares of Integra LifeSciences from $24.00 to $12.00 and set an "underweight" rating for the company in a research note on Tuesday, May 6th. Wells Fargo & Company lowered their price target on shares of Integra LifeSciences from $25.00 to $13.00 and set an "equal weight" rating on the stock in a report on Tuesday, May 6th. Finally, JMP Securities cut their price objective on Integra LifeSciences from $35.00 to $25.00 and set a "market outperform" rating for the company in a report on Friday, May 9th.

Institutional Investors Weigh In On Integra LifeSciences

A number of large investors have recently bought and sold shares of the business. Norges Bank bought a new stake in shares of Integra LifeSciences during the 4th quarter worth about $8,967,000. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. raised its stake in shares of Integra LifeSciences by 3.9% in the 4th quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 38,466 shares of the life sciences company's stock valued at $872,000 after acquiring an additional 1,437 shares in the last quarter. GAMMA Investing LLC lifted its holdings in Integra LifeSciences by 3,595.1% in the 1st quarter. GAMMA Investing LLC now owns 23,353 shares of the life sciences company's stock worth $5,140,000 after purchasing an additional 22,721 shares during the last quarter. Principal Financial Group Inc. boosted its position in Integra LifeSciences by 5.5% during the fourth quarter. Principal Financial Group Inc. now owns 423,432 shares of the life sciences company's stock worth $9,603,000 after purchasing an additional 22,000 shares during the period. Finally, Arrowstreet Capital Limited Partnership grew its holdings in Integra LifeSciences by 7.1% during the fourth quarter. Arrowstreet Capital Limited Partnership now owns 13,756 shares of the life sciences company's stock valued at $312,000 after purchasing an additional 913 shares during the last quarter. 84.78% of the stock is currently owned by institutional investors.

Integra LifeSciences Trading Down 1.9%

Shares of IART traded down $0.24 during midday trading on Friday, hitting $12.15. The stock had a trading volume of 1,342,194 shares, compared to its average volume of 1,048,561. The business has a 50-day simple moving average of $14.24 and a two-hundred day simple moving average of $20.04. The firm has a market cap of $944.18 million, a P/E ratio of -31.97, a price-to-earnings-growth ratio of 0.69 and a beta of 1.16. The company has a current ratio of 1.21, a quick ratio of 0.72 and a debt-to-equity ratio of 0.81. Integra LifeSciences has a fifty-two week low of $11.60 and a fifty-two week high of $32.66.

Integra LifeSciences (NASDAQ:IART - Get Free Report) last posted its quarterly earnings data on Monday, May 5th. The life sciences company reported $0.41 EPS for the quarter, missing analysts' consensus estimates of $0.43 by ($0.02). The firm had revenue of $382.65 million during the quarter, compared to analyst estimates of $381.17 million. Integra LifeSciences had a positive return on equity of 12.12% and a negative net margin of 1.78%. The company's revenue for the quarter was up 3.7% on a year-over-year basis. During the same period in the prior year, the business posted $0.55 EPS. As a group, equities analysts forecast that Integra LifeSciences will post 2.45 EPS for the current year.

Integra LifeSciences Company Profile

Integra LifeSciences Holdings Corporation manufactures and sells surgical instruments, neurosurgical products, and wound care products for use in neurosurgery, neurocritical care, and otolaryngology. It operates in two segments, Codman Specialty Surgical and Tissue Technologies. The company offers neurosurgery and neuro critical care products, including tissue ablation equipment, dural repair products, cerebral spinal fluid management devices, intracranial monitoring equipment, and cranial stabilization equipment; and surgical headlamps and instrumentation, as well as after-market services.